Mode
Text Size
Log in / Sign up

Radiofrequency ablation for long-standing persistent AF shows intraprocedural conversion patterns linked to 1-year outcomes.

Radiofrequency ablation for long-standing persistent AF shows intraprocedural conversion patterns li…
Photo by philippe spitalier / Unsplash
Key Takeaway
Note that sequential intraprocedural AF-AFL-SR conversion, not direct AF termination, predicted better 1-year outcomes in this cohort.

This retrospective cohort study included 260 consecutive patients with long-standing persistent atrial fibrillation (AF lasting >12 months) at a single center. All underwent de novo radiofrequency catheter ablation using a standardized '2C3L plus' strategy, combining pulmonary vein isolation with linear and complex fractionated atrial electrogram ablation. The primary outcome was freedom from any documented atrial tachyarrhythmia lasting >30 seconds, off antiarrhythmic drugs, at 1-year follow-up.

Intraprocedural AF termination was achieved in 103 of 260 patients. Intraprocedural conversion to atrial flutter (AFL) was achieved in 90 of 260 patients and was associated with a reduced recurrence risk (adjusted HR: 0.306; 95% CI: 0.133–0.704, P = 0.005). Sequential intraprocedural conversion of AF-AFL-SR was a strong and independent predictor of arrhythmia-free survival (adjusted HR: 0.305; 95% CI: 0.119–0.784, P = 0.014).

In contrast, acute termination of AF directly to sinus rhythm was not associated with a lower risk of recurrence (adjusted HR: 0.765; 95% CI: 0.410–1.428, P = 0.400). Safety data, including adverse events, serious adverse events, discontinuations, and tolerability, were not reported.

Key limitations include the retrospective, single-center design and lack of a comparator group. The findings suggest that intraprocedural organization of AF-AFL-SR may be a meaningful prognostic endpoint, but causal inferences cannot be drawn. Clinicians should interpret these results as hypothesis-generating for procedural planning in persistent AF.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
BackgroundLong-standing persistent atrial fibrillation (LSPAF) remains a challenge of catheter ablation. The efficiency and optimal procedural endpoints of “2C3L plus” approach—a strategy combining pulmonary vein isolation (PVI) with linear and complex fractionated atrial electrogram (CFAEs) ablation—is unclear.MethodsThis single-center, retrospective cohort study included 260 consecutive patients with LSPAF (defined as continuous AF lasting > 12 months) who underwent de novo radiofrequency catheter ablation between January 2020 and January 2022. All patients received a standardized “2C3L plus” strategy. The primary endpoint was freedom from any documented atrial tachyarrhythmia lasting >30 s, off antiarrhythmic drugs, at 1-year follow-up. Predictors of recurrence were analyzed using multivariable Cox regression analysis.ResultsIntraprocedural atrial fibrillation (AF) termination was achieved in 103 of 260 (39.6%) patients and 90 (34.6%) patients converted to atrial flutter (AFL) during ablation. Acute termination of AF directly to sinus rhythm (SR) was not associated with a lower risk of recurrence (adjusted HR: 0.765, 95% CI: 0.410–1.428, P = 0.400). However, intraprocedural conversion from AF to AFL was associated with significantly reduced recurrence risk (Uni: HR: 0.319, 95% CI: 0.142–0.714, P = 0.005; adjusted HR: 0.306, 95% CI: 0.133–0.704, P = 0.005). Further analysis revealed that the sequential intraprocedural conversion of AF-AFL-SR during ablation was a strong and independent predictor of arrhythmia-free survival (Uni: HR: 0.275, 95% CI: 0.108–0.696, P = 0.006; adjusted HR: 0.305, 95% CI: 0.119–0.784, P = 0.014).ConclusionIn patients with LSPAF undergoing extensive “2C3L Plus” substrate ablation, the intraprocedural organization of AF-AFL-SR, rather than AF termination itself, emerged as a powerful independent predictor of 1-year arrhythmia-free survival, suggesting its value as a more meaningful prognostic endpoint.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.